Items tagged with Research and development

Fighting the white plague (post with simple image)

Today is World TB Day. More people die of tuberculosis in South Africa than from any other disease.

Punked by pharma: Public funds for private products (post with simple image)

Tax dollars are making it easier for the drug and diagnostics industry to develop and market essential TB products. Is the public getting a fair return on its investment?  

Novartis provides drug candidate compounds to TB Alliance (post with simple image)

Exclusive worldwide license from Novartis includes a novel class of drugs that is active against drug sensitive and multi-resistant strains of tuberculosis.

Killer TB spreads as research plummets (post with simple image)

Initiatives to support antibiotic research — of which TB drug and diagnostic R&D are crucial parts — must be backed by funding commensurate to the growing size of the epidemic.

TAG: Tuberculosis research at risk as big pharma shutters programs (post with simple image)

TAG’s ninth annual Report on Tuberculosis Research Funding Trends shows that the foundation of the TB research enterprise is shakier than ever, setting back efforts to fight a disease that in 2012 killed 1.3 million people and caused 8.6 million to fall sick.

Is AstraZeneca getting ready to exit antibiotics research? (post with simple image)

For the past year, the fate of antibiotics R&D at AstraZenecahas been uncertain. The drug maker, which possesses what is generally regarded as having the strongest antibiotics pipeline in the pharmaceutical industry, indicated that spending on this area would be reduced as part of a larger cutback and strategic refocusing. Ever since, speculation has grown that antibiotics may be abandoned altogether.

#CoughUpTheTBMoney: Civil society calls for tripling of money for TB research (post with simple image)

Today at the opening plenary of the 45th Conference on Lung Health in Barcelona, activists from across the globe called on governments to dramatically increase spending on R&D for new treatments for TB. Spending must be tripled to meet the US$2 billion annual minimum required according to the Stop TB Partnership’s Global Plan to Stop TB.

2014 Access to Medicine Index – More being done, but progress is uneven (post with simple image)

17 November 2014 | The world’s leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years. However, the industry struggles to perform well in some practices that matter, according to the 2014 Access to Medicine Index, published Monday.

Developing a drug costs $2.6 billion, but not everyone believes this (post with simple image)

The cost to develop a new drug and win FDA marketing approval is now pegged at nearly $2.6 billion, according to a new report from the Tufts Center for the Study of Drug Development. The estimate will likely hearten drug makers that argue rising prices reflect rising costs, but consumer advocates reacted as if someone was trying to sell them a bridge.

New report estimates that failure to address drug-resistant TB and other infections will cause $100 trillion economic loss by 2050 (post with simple image)

Spending on TB research from private-sector companies dropped 11.8% from 2012 to 2013 to less than $100 million. The status quo of declining investment in developing new TB drugs must end.

Page 13 of 18 · Total posts: 0

←First 12 13 14 Last→